A phase 1b study of agatolimod (TLR9) in malignant melanoma in addition to treatment with checkpoint inhibitors
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Agatolimod (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 21 Jan 2025 New trial record